Forest Ray PhD,  —

Pulnovo Medical recently raised an undisclosed amount totaling millions of dollars in investment funding to support clinical trials and product development related to pulmonary arterial hypertension (PAH). “The road of global medical innovation has never been an easy journey,” Cynthia Chen, Pulnovo’s executive president, said in a…

An investigational therapy called R-107 completely stopped the progression of pulmonary arterial hypertension (PAH) in a rat model and may become the first medicine to reverse the increasing blood pressure characteristic of the disease, a study suggested. Now, R-107’s developer, Claritas Pharmaceuticals, plans to begin clinical testing…

The U.S. Food and Drug Administration (FDA) has granted priority review status to the application seeking approval of Tyvaso DPI — a dry powder inhaled formulation of treprostinil — for the treatment of both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Priority review shortens…

Scientists have created a new “cellular blueprint” of healthy lung cells that provides a reference against which tissue from lungs affected by conditions like pulmonary hypertension (PH) can be compared. The ability to accurately map the differences between healthy and diseased lungs can help researchers find new therapeutic approaches,…

People with pulmonary hypertension (PH) are invited to apply for $500 micro-grants offered by Team PHenomenal Hope to help cover non-medical needs they are struggling to meet due to the COVID-19 pandemic and how it affected them financially. The grants, offered through nonprofit’s Unmet Needs Patient Impact Fund, can be…

On May 5, the Pulmonary Hypertension Association (PHA) will join more than 80 organizations around the world in marking World Pulmonary Hypertension (PH) Day and seeking to raise awareness of the rare disease through webinars and on social media. Part of this year’s focus amid the ongoing…

The Pulmonary Hypertension Association (PHA) has published a guide to educate healthcare providers and parents on persistent pulmonary hypertension of the newborn (PPHN). The goal, the PHA said, is to help identify the disease right away, so as to start early treatment to prevent complications for the baby.

The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected to pose little risk to the rare disease community, including to patients with compromised immune systems or those participating in gene therapy studies. That was the message of a recent…

Tenax Therapeutics has acquired PH Precision Med (PHPM), a private biotech focused on developing imatinib as a treatment for pulmonary arterial hypertension (PAH). “The acquisition of PHPM immediately expands Tenax’s pipeline to include a second de-risked Phase 3 ready candidate with the potential to be the first…

The prolargin protein may serve as a biomarker for pulmonary arterial hypertension (PAH), allowing for earlier diagnosis and differentiating among different types of pulmonary hypertension (PH), according to a recent study. The study, “Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension,” was…

Dialing up the activity of a gene called IRF7  may reduce pulmonary artery thickening, lower blood pressure, and ease inflammation in people with pulmonary hypertension (PH), a study using a rat model of the disease suggests. The study, “Downregulation of Interferon regulatory factor 7 is link…

Combined with sildenafil, the potential therapy NTP42 eased symptoms of pulmonary arterial hypertension (PAH) in a rat model of the disease, a study reported. Further testing with other approved treatments is warranted, its researchers wrote, as the paired treatment showed more benefit than either sildenafil (sold as Revatio,…